As of Feb 21, 2025, Regeneron Pharmaceuticals, Inc. Intrinsic Value is $979.5. This suggests it may be undervalued by 39.9% compared to its current price of around $700.3.
As of Feb 21, 2025, Regeneron Pharmaceuticals, Inc.'s Discounted Cash Flow (DCF) valuation estimates its share price at $1,253.8. This suggests it may be overvalued by 79.0% to its current price of around $700.3, using a discount rate of 7.4% and terminal growth rate of 3.0%.
Regeneron Pharmaceuticals, Inc. is currently considered undervalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $979.5, compared to a market price of around $700.3. This suggests a potential undervaluation of 39.9%.